Adagene is a clinical-stage biopharma firm developing antibody-based immunotherapies with proprietary platforms that optimize therapeutic epitopes and cross-reactivity. Its ADG pipeline focuses on oncology indications utilizing monospecific and conjugated antibody formats. Strategic partnerships include collaborations with Exelixis, Sanofi, Roche, and recently ConjugateBio, aimed at advancing targeted therapies in solid tumors.

(Last Price 1.91): Lacking any evidence of a turn higher, such as a five-wave advance, there is scope for lower in wave (ii) towards 1.7 -1.85, the 61.8% retracement levels of wave 1. Trading above wave ii extreme at 2.05, will suggest the trend has turned higher.